In this file photo taken on May 18, 2020, a syringe is pictured on an illustration representation of COVID-19, the disease caused by the novel coronavirus in Paris. The Paris prosecutor's office said on July 10, 2020, that it was investigating "massive fraud" across France by people falsely claiming temporary wage assistance for employees laid off during the coronavirus lockdown. JOEL SAGET / AFP
The US biotech firm Moderna said Tuesday it would enter the final stage of its human trials for its COVID-19 vaccine on July 27, after promising early results were published in a journal.
The Phase 3 trial will recruit 30,000 participants in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half will receive a placebo.
It is designed to learn whether the vaccine can prevent infection by the SARS-CoV-2 virus, or, if people still get infected, whether it can prevent the infection progressing toward symptoms.
If they do get symptoms, the vaccine can still be considered a success if it stops severe cases of COVID-19.
The study should run until October 27, according to its page on clinicaltrials.gov.
The announcement came after the New England Journal of Medicine on Tuesday published results from the first stage of Moderna’s vaccine trial, which showed the first 45 participants all developed antibodies to the virus.
Moderna is in pole position in the global race to find a vaccine against the coronavirus, which has infected more than 13.2 million people and killed 570,000.
China’s SinoVac is also at an advanced stage, Phase 2, while the Russian news agency TASS has announced Russian researchers have completed clinical trials on a vaccine, though they have not shared data.
Scientists caution that the first vaccines to come to market may not be the most effective or safest.
The Moderna vaccine belongs to a new class of vaccine that uses genetic material, in the form of RNA, to encode the information needed to grow the virus’ spike protein inside the human body, in order to trigger an immune response.
The spike protein is a part of the virus it uses to invade human cells, but by itself is relatively harmless.
The advantage of this technology is that it bypasses the need to manufacture viral proteins in the lab, shaving months off the standardization process and helping to ramp up mass production.
But no vaccines based on this platform have previously received regulatory approval.
AFP
This was contained in a circular dated April 8, 2024 and directed to all banks…
This means that Muslims will celebrate Eid-el-Fitr on Wednesday, 10th April 2024.
Jackrich, an ex-Niger Delta agitator, was arrested by men dressed in military camouflage.
The players and officials were supposed to fly into Spain on Tuesday afternoon for the tournament…
The lawmakers claimed to be speaking on behalf of at least 60 lawmakers in the…
Besides economic consequences, tobacco smoking is considered a leading cause of preventable deaths and morbidity,…